Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2026-05-20 Report Publication Anno…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2026
Report Publication Announcement Classification · 95% confidence The document is a preliminary announcement stating the date and links for the upcoming half‐year (Q2) financial report publication under the German Securities Act. It contains no financial data itself but merely notifies investors of the report’s disclosure date and where to access it. Under the “menu vs meal” rule, this qualifies as a Report Publication Announcement, not the report itself.
2026-05-20 English
Hinweis auf Halbjahresfinanzbericht vom 01.10.2025 bis zum 31.03.2026
Report Publication Announcement Classification · 97% confidence The document is a brief notice informing stakeholders that the half-year financial report (covering 01.10.2025 to 31.03.2026) is available online and specifying publication dates and platforms. It does not contain the actual report’s financial data but merely announces its availability. This fits the criteria for a Report Publication Announcement (RPA).
2026-05-20 German
Hinweis auf Halbjahresfinanzbericht vom 01.10.2025 bis zum 31.03.2026
Report Publication Announcement Classification · 95% confidence The document is a brief notice indicating that the half-year financial report for the period 01.10.2025–31.03.2026 is available online via a provided URL. It does not contain the actual financial statements or substantive data but merely announces the publication and availability of the report. Under the “menu vs meal” rule, this is a report publication announcement, not the report itself.
2026-05-20 German
BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology
Regulatory Filings Classification · 90% confidence The document is a corporate press release (Regulatory News) announcing that BRAIN Biotech has been granted a key patent. It contains no financial results, dividend, management changes, M&A activity, or other specific events covered by the defined categories. It is not the text of a report itself, nor a notice of report publication. Therefore it falls into the fallback Regulatory Filings category (RNS).
2026-03-23 English
Results of the 2026 Annual General Meeting for the 2024/25 financial year of BRAIN Biotech AG
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement detailing the results of an Annual General Meeting (AGM), including shareholder approval of agenda items and the election of a new Supervisory Board member. While it discusses the meeting, it is a summary announcement of the results rather than the full presentation materials (AGM-R) or the formal voting results filing (DVA). Given the nature of the content as a corporate news release summarizing the outcome of the meeting, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-11 English
BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
Earnings Release Classification · 100% confidence The document is a corporate press release announcing the financial results for the first three months (3M) of the fiscal year 2025/26. It provides key highlights, segment performance, and outlook, but explicitly directs the reader to a separate link for the full '3M Report'. Following the 'Menu vs Meal' rule, this document is an announcement of financial results rather than the full interim report itself, making it an Earnings Release (ER). Q1 2026
2026-02-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.